Evicenter
MarkdownMedical informationP&T meetings
Descartes-08

Generalized myasthenia gravis

Launch
Not announced
Last updated
177 sources

Clinical evidence

AURORA

34 evidence topics · 10 sources

Objective
Location and study date
Registry site count and site locations by country
CountrySite locations listed in the registry
United States“Tucson, Arizona, United States, 85718”; “Carlsbad, California, United States, 92011”; “Los Angeles, California, United States, 90095”; “Orange, California, United States, 92868”; “Aurora, Colorado, United States, 80045”; “Washington D.C., District of Columbia, United States, 20007”; “Maitland, Florida, United States, 32751”; “Tampa, Florida, United States, 33612”; “O'Fallon, Illinois, United States, 62269”; “Fairway, Kansas, United States, 66205”; “Lexington, Kentucky, United States, 40536”; “Boston, Massachusetts, United States, 02111”; “Amherst, New York, United States, 14226”; “New York, New York, United States, 10027”; “New York, New York, United States, 10065”; “Chapel Hill, North Carolina, United States, 27599”; “Charlotte, North Carolina, United States, 28204”; “Portland, Oregon, United States, 97239”; “Philadelphia, Pennsylvania, United States, 19104”; “Pittsburgh, Pennsylvania, United States, 15213”; “Houston, Texas, United States, 77030”; “Seattle, Washington, United States, 98195”; “Milwaukee, Wisconsin, United States, 53215”
Canada“Toronto, Canada”
Italy“Rome, Italy”
Poland“Krakow, Poland”
Serbia“Belgrade, Serbia”
Spain“Barcelona, Spain”; “Madrid, Spain”
Turkey“Ankara, Turkey (Türkiye)”; “Istanbul, Turkey (Türkiye)”
United Kingdom“Birmingham, United Kingdom”; “Sheffield, United Kingdom”
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using MG-ADL response as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets

No evidence found.

Results
Participant disposition

No evidence found.

Baseline characteristics

No evidence found.

Efficacy results

No evidence found.

Health-related quality of life and patient-reported outcomes

No evidence found.

Safety results

No evidence found.

Study limitations
Summary
  • AURORA has reported no efficacy or safety results. The registry record (last update posted 2026-09-01) lists the study as active and not recruiting, with estimated primary completion on 2026-12-30 and estimated study completion on 2027-09-30; record version 16 had listed estimated primary completion on 2026-11-30. The company expects a data readout in the first quarter of 2027.
  • Enrollment differs by source: the company states approximately 100 participants, registry record version 16 listed an estimated enrollment of 100, and the current registry record lists an actual enrollment of 128.
  • The primary endpoint is the proportion of participants with an MG-ADL improvement of 3 points or more at month 4 compared with placebo. The registry lists a crossover assignment model, a double-blind Part 1 of about 6 months, and an open-label Part 2 of about 8 months for eligible participants, and the company trial schema shows optional Descartes-08 infusions with follow-up at months 5, 6, 9, and 12.
  • The phase 2b report stated plans to use the MGC score as the primary outcome in a subsequent phase 3 trial; in AURORA, MGC improvement of 4 points or more at month 4 is a secondary endpoint. One publication reports that the MG-ADL score was considered “a bar too low” for approval of a therapy given the 2-point threshold for clinically meaningful improvement. Another reports that a 3-point MG-ADL change had a specificity of 90% and a sensitivity of 62%, that no publicly available FDA guidance on an MG-ADL responder threshold exists, and that the eculizumab label refers to REGAIN results using a 3-point improvement.
  • Eligibility is limited to adults with an anti-AChR antibody titer or anti-AChR cluster antibody above the reference upper normal limit, MGFA class 2 to 4, and an MG-ADL total score of 6 or more. Participants diagnosed within 12 months of screening, those with no history of systemic gMG treatment other than acetylcholinesterase inhibitors, those treated with rituximab or ocrelizumab within 12 months, and those with prior BCMA-directed therapy are excluded. In the phase 2b mITT population, 6 participants (23.1%) were triple seronegative and 1 (3.8%) was LRP4 autoantibody-positive.
  • The company's Form 10-K states that a trial conducted under a Special Protocol Assessment agreement that meets its endpoints carries no guarantee that the FDA will accept or approve a marketing application.